ARF3 and prostate carcinoma: This was corroborated in prostate cancer by a lack of consistent alteration in independent datasets comparing ARF3 mRNA levels across prostate normal tissue, primary tumor or metastasis (Fig. 9, A–E), or in the TCGA prostate adenocarcinoma dataset (PRAD Prostate; normal, n = 86; tumor, n = 323) for normal versus primary tumor or across Gleason Grades (Fig. S5, C and D).